<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37357964</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>229</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.</ArticleTitle><Pagination><StartPage>805</StartPage><EndPage>812</EndPage><MedlinePgn>805-812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiad222</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Novel oral poliovirus vaccine (OPV) type 2 (nOPV2) has been made available for outbreak response under an emergency use listing authorization based on supportive clinical trial data. Since 2021 more than 350 million doses of nOPV2 were used for control of a large outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Nigeria.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a bayesian time-series susceptible-infectious-recovered model, we evaluate the field effectiveness of nOPV2 immunization campaigns in Nigeria compared with campaigns using monovalent OPV type 2 (mOPV2).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that both nOPV2 and mOPV2 campaigns were highly effective in reducing transmission of cVDPV2, on average reducing the susceptible population by 42% (95% confidence interval, 28-54%) and 38% (20-51%) per campaign, respectively, which were indistinguishable from each other in this analysis (relative effect, 1.1 [.7-1.9]). Impact was found to vary across areas and between immunization campaigns.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results are consistent with the comparable individual immunogenicity of nOPV2 and mOPV2 found in clinical trials but also suggest that outbreak response campaigns may have small impacts in some areas requiring more campaigns than are suggested in current outbreak response procedures.</AbstractText><CopyrightInformation>© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voorman</LastName><ForeName>Arend</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6242-7796</Identifier><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Hil</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuaib</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamu</LastName><ForeName>Usman S</ForeName><Initials>US</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korir</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>World Health Organization, Nigeria Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erbeto</LastName><ForeName>Tesfaye</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>World Health Organization, Nigeria Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-8395-2001</Identifier><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okiror</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">mass vaccination</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">susceptible infected recovered models</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. A. V., H. L., A. S. B., and S. O. are employed by the Bill &amp; Melinda Gates Foundation. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37357964</ArticleId><ArticleId IdType="pmc">PMC10938209</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad222</ArticleId><ArticleId IdType="pii">7207511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garon  J, Seib  K, Orenstein  WA, et al.  Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines  2016; 15:693–708.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin  GR, O’Reilly  KM, Grassly  NC, et al.  Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccine. Science  2020; 368:401–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin  G, Peak  C, Eisenhawer  M, et al.  Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine  2022; 41 (suppl 1):A122–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin  J, Burns  CC, Jorba  J, et al.  Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing—worldwide, March–October 2021. MMWR Morb Mortal Wkly Rep  2022; 71:786–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay  AS, Zipursky  S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect Dis  2023; 23:e67–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">36162417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill  M, Bandyopadhyay  AS, Pollard  AJ. Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet  2022; 400:713–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35988575</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster  I, Leroux-Roels  I, Bandyopadhyay  AS, et al.  Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet  2021; 397:39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens  X, Bandyopadhyay  AS, Gast  C, et al.  Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet  2021; 397:27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme  P, De Coster  I, Bandyopadhyay  AS, et al.  The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet  2019; 394:148–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca  PA, Wright  PF, John  TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis  1990; 13:926–39.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly  NC, Wenger  J, Durrani  S, et al.  Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet  2007; 369:1356–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448821</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins  HE, Aylward  RB, Gasasira  A, et al.  Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med  2008; 359:1666–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy  SB, Macklin  GR, Mason Ross  G, et al.  Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey. Lancet Glob Health  2023; 11:e917–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187988</ArticleId><ArticleId IdType="pubmed">37202026</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare  M, Selinger  C, McCarthy  KA, Eckhoff  PA, Chabot-Couture  G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. PLoS Biol  2018; 16:e2002468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942853</ArticleId><ArticleId IdType="pubmed">29702638</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyesh-Melnick  M, Melnick  JL, Rawls  WE, et al.  Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol  1967; 86:112–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">4378110</ArticleId></ArticleIdList></Reference><Reference><Citation>Gast  C, Bandyopadhyay  AS, Sáez-Llorens  X, et al.  Fecal shedding of 2 novel live attenuated oral poliovirus type 2 vaccine candidates by healthy infants administered bivalent oral poliovirus vaccine/inactivated poliovirus vaccine: 2 randomized clinical trials. J Infect Dis  2021; 226:852–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470102</ArticleId><ArticleId IdType="pubmed">34610135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson  AL, Zaman  K, Hoque  M, et al.  Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis doi:10.1016/S1473-3099(23)00139-1. Published 10 May 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00139-1</ArticleId><ArticleId IdType="pmc">PMC10503264</ArticleId><ArticleId IdType="pubmed">37178706</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns  CC, Shaw  J, Jorba  J, et al.  Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in Northern Nigeria. J Virol  2013; 87:4907–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamage  D, Mach  O, Palihawadana  P, et al.  Boosting of mucosal immunity after fractional-dose inactivated poliovirus vaccine. J Infect Dis  2018; 218:1876–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161111</ArticleId><ArticleId IdType="pubmed">29982532</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman  A, Lyons  H, Bennette  C, et al.  Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine  2022; 41  Suppl 1:A85–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10973941</ArticleId><ArticleId IdType="pubmed">35339308</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens  FR, Gaughan  AE, Linard  C, Tatem  AJ. Disaggregating census data for population mapping using random forests with remotely-sensed and ancillary data. PLoS One  2015; 10:e0107042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331277</ArticleId><ArticleId IdType="pubmed">25689585</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakkar  N, Gilani  SSA, Hasan  Q, McCarthy  KA. Decreasing measles burden by optimizing campaign timing. Proc Natl Acad Sci U S A  2019; 116:11069–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561209</ArticleId><ArticleId IdType="pubmed">31085656</ArticleId></ArticleIdList></Reference><Reference><Citation>

Dong  TQ, Wakefield  J. Estimating efficacy of measles supplementary immunization activities via discrete-time modeling of disease incidence time series. arXiv  [Preprint: not peer reviewed]. 17 October 2020. Available from:  https://arxiv.org/abs/2010.08875.</Citation></Reference><Reference><Citation>McCarthy  KA, Chabot-Couture  G, Shuaib  F. A spatial model of wild poliovirus type 1 in Kano State, Nigeria: calibration and assessment of elimination probability. BMC Infect Dis  2016; 16:521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5041410</ArticleId><ArticleId IdType="pubmed">27681708</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander  JP, Gary  HE, Pallansch  MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis  1997; 175:S176–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203713</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Reilly  KM, Durry  E, ul Islam  O, et al.  The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001–11: a retrospective analysis. Lancet  2012; 380:491–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418593</ArticleId><ArticleId IdType="pubmed">22766207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>